Follow
Roche anti-aggregated beta-amyloid monoclonal fails in phase III.
"The Swiss drugmaker said on Monday that two phase 3 trials of its antibody drug gantenerumab did not slow the decline in people with early- stage Alzheimer’s disease, with both failing to meet their “primary endpoint”, or most important research objective."
https://www.ft.com/content/df20b1b7-6368-44bb-803d-b8602d575275
